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Abstract 
Objective: This study aimed to describe the clinical, endoscopic, and histologic 
characteristics, as well as the response to conventional treatment of pediatric patients 
with the classical form of eosinophilic esophagitis (EoE).
Methods: Study of clinical, laboratory, endoscopic, and histologic data and response to 
conventional treatment of 43 previously followed pediatric patients with the classical 
form of EoE.
Results: A total of 43 patients diagnosed with EoE were included in the study, of which 
37 were males (86%), with a mean age of 8.4 years. The most common symptoms were: 
nausea, vomiting, and abdominal pain (100%) in children younger than 7 years, and 
loss of appetite (60%), heartburn (52%), and food impaction (48%) in children older 
than 7 years and adolescents. Regarding the endoscopic findings, 12 (28%) patients 
had whitish plaques on the esophageal lining, 8 (18.5%) had longitudinal grooves, 2 
(4.5%) had concentric rings, 3 (7%) had longitudinal grooves and whitish plaques, and the 
remaining 18 (42%) had esophageal mucosa with normal appearance. Despite the initial 
favorable response, 76.7% of patients required more than one course of corticosteroid 
therapy (systemic or aerosol) and diet (exclusion or elimination of food or elementary 
Este é um artigo Open Access sob a licença de CC BY-NC-ND
198 Rodrigues M et al.
PALAVRAS-CHAVE
Esofagite eosinofílica;
Refluxo 
gastroesofágico
Manifestações clínicas, terapêutica e evolução de crianças e adolescentes com eso-
fagite eosinofílica
Resumo 
Objetivo: O objetivo deste estudo foi descrever as características clínicas, endoscópicas e 
histológicas, assim comoa resposta ao tratamento convencional de pacientes pediátricos 
com a forma clássica de esofagite eosinofílica (EEo).
Métodos: Levantamento de dados clínicos, laboratoriais, endoscópicos, histológicos e 
da resposta ao tratamento convencional de 43 pacientes pediátricos acompanhados 
previamente com a forma clássica de EEo.
Resultados: Foram incluídos 43 pacientes com diagnóstico de EEo, sendo 37 do 
sexo masculino (86%), com idade média de 8,4 anos. Os sintomas mais encontrados 
foram: náusea, vômito e dor abdominal (100%) em crianças menores de sete anos; e 
inapetência (60%), queimação retroesternal (52%) e impactação alimentar (48%) em 
crianças maiores de sete anos e adolescentes. Em relação aos achados endoscópicos, 
12 (28%) pacientes apresentavam placas esbranquiçadas na mucosa do esôfago, oito 
(18,5%) sulcos longitudinais, dois (4,5%) anéis concêntricos, três (7%) sulcos longitudinais 
e placas esbranquiçadas, e os outros 18 (42%) apresentavam aparência normal da mucosa 
esofágica. Apesar da resposta favorável inicial, 76,7% dos pacientes necessitaram 
realizar mais de um ciclo terapêutico com corticoterapia (aerossol ou sistêmica) e dieta 
(de exclusão ou eliminação dos alérgenos alimentares ou elementares). Persistência 
do infiltrado eosinofílico foi encontrada em uma parcela dos pacientes, a despeito da 
resposta clínica favorável.
Conclusões: A forma clássica da EEo apresenta sintomas diferentes segundo a faixa 
etária. Parcela expressiva dos pacientes necessitou de mais de um ciclo terapêutico para 
apresentar remissão clínica. Observou-se melhora endoscópica e histológica; no entanto, 
a infiltração eosinofílica persistiu em parcela dos pacientes.
© 2013 Sociedade Brasileira de Pediatria. Publicado por Elsevier Editora Ltda.  
Introduction
Eosinophilic esophagitis (EoE) was described in the late 
1970s by Landers et al.,1 and has been identified as a 
clinical pathological entity since 1993 by Attwood et al.2 
The Brazilian scientific literature in pediatrics is limited to 
two case series described by Cury et al.3 and by Ferreira 
et al.4 
Considering the recent and rapid evolution in the 
understanding of this condition, a group of researchers has 
updated the latest consensus on EoE,5 characterizing it as 
an immunological esophageal disease with chronic evolution 
and frequent relapses, whose clinical manifestations are 
related to esophageal dysfunction and, histologically, to 
the presence of eosinophil accumulation in the esophageal 
mucosa more than 15 eosinophils per high-power field (HPF), 
in the absence of eosinophil infiltration in the gastric and 
duodenal mucosa. The symptoms and pathological findings 
should improve with medical treatment, which involves the 
exclusion of allergens (food or aeroallergens), use of topical 
corticosteroids, or both therapeutic measures. A subset of 
patients responsive to proton pump inhibitors (PPIs) has 
also been described, termed PPI responders, differentiating 
them from the group of patients with classic EoE, known 
as non-PPI-responders. All other recognized causes of EoE 
should be excluded, as there are no symptoms identified 
at physical examination, serum markers or pathognomonic 
endoscopic data of the disease.5 
The aim of this retrospective study was to describe the 
clinical, endoscopic, and histological characteristics and 
response to conventional treatment of pediatric patients 
with the classical form of EoE. 
allergens). Persistence of eosinophil infiltration was found in some patients despite 
favorable clinical response.
Conclusions: The classic form of EoE typically shows different symptoms according age 
range. A significant number of patients required more than one treatment cycle to 
show clinical remission. Endoscopic and histologic improvement was observed; however, 
eosinophilic infiltration persisted in some patients.
© 2013 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda.  
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Methods
This was a retrospective study using data collection in a series 
of cases addressing the clinical, laboratory, endoscopic, and 
histological data from the records of 43 patients treated in 
the period between February, 2004 and September, 2010 
with a diagnosis of EoE in the Gastroenterology Outpatient 
Clinic of the Hospital das Clínicas da Faculdade de Medicina 
da Universidade de São Paulo (HCFMUSP).
Inclusion criteria
All patients were referred to the specialized service with 
a history of previous upper endoscopy in their healthcare 
services of origin, with an initial diagnosis of reflux 
esophagitis resistant to treatment with PPI for at least 
three months. 
All patients were symptomatic. After obtaining the 
clinical history, physical examination was performed 
and personal or family history of first-degree atopy was 
assessed; subsequently, patients underwent a new upper 
endoscopy. Two fragments of the esophagus were obtained 
(one proximal and one distal), as well as two fragments 
of the stomach and duodenum through upper endoscopy 
and biopsy forceps for histological evaluation. The number 
of eosinophils per high-magnification field (x400) was 
quantified in at least 10 fields; EoE was considered when ≥ 
15 eosinophils/HPF5 were found in the esophageal mucosa 
in at least 2 high-power fields and normal gastric and 
duodenal mucosa. 
The presence of specific serum immunoglobulin E (IgE) 
was analyzed (ImmunoCAP®)6 for the suspected food 
according to clinical history, to assist in the identification 
of food allergens involved in the EoE process, according to 
the standard method, considered positive when ≥ class II. 
Exclusion criteria
All other known causes of EoE were excluded, such as 
gastroesophageal reflux disease (GERD), celiac disease, 
Crohn’s disease, infection, hypereosinophilic syndrome, 
achalasia, drug hypersensitivity, vasculitis, pemphigus 
vegetans, connective tissue disease, and graft-versus-host 
disease. 
As recommended in the consensus of 2007,7 the possibility 
of GERD was ruled out by the lack of response to previous 
treatment with PPI. 
The therapeutic modality adopted by the patients of the 
present study was in accordance with recent data from 
the literature on EoE.5,7 PPI is not considered the primary 
treatment for EoE, but can be used as adjunctive therapy 
to relieve some of the symptoms. Systemic corticosteroid 
therapy was used for children younger than 2 years and 
topical therapy for the other patients. In the first case, 
prednisolone 1 mg/kg/day was used, divided in two daily 
doses for four weeks, with scheduled withdrawal up to the 
eighth week. In the second case, fluticasone propionate 
was used by oral route (children 2 to 4 years: 176 mcg 
daily; children 5 to 10 years: 444 mcg daily; adolescents 
> 11 years: 880 mcg daily). A suitable topical dose was 
administered in the form of an oral spray, divided in two 
doses per day. Patients were instructed not to use the 
spacer and that the content of the spray must be swallowed 
and not aspirated, and patients were not allowed to eat or 
drink for at least 30 minutes after medication. Treatment 
with fluticasone was carried out for three months. 
Dietary therapy (removal of specific antigens or 
elementary diet) was patient-specific and considered as an 
effective part of the treatment, with adequate calories, 
vitamins, and micronutrients of the received diet at 
baseline and at follow-up.7
Patients were followed through regular visits to the 
outpatient clinic every two months, where parents and 
patients were asked about symptoms, treatment adherence, 
and side effects of drug therapy. The monitoring of upper 
endoscopy was recommended after 9 to 12 months of 
treatment initiation. 
This study was approved by the Ethics Committee of the 
Department of Gastroenterology of HCFMUSP. 
Results
Of the 43 patients, 37 were males (86%), and 41 were 
defined by their parents as white and two as black. Patient’s 
age ranged from 1 month to 17 years, with a mean of 8.4 
years. Approximately 44% of patients were identified by 
clinical history as having respiratory allergies, and 23% of 
first-degree relatives had respiratory, gastrointestinal, or 
skin atopy. The clinical manifestations of the 43 patients 
are shown in Table 1. Nausea, vomiting, and abdominal 
pain were more frequent in patients aged less than 7 years, 
while food aversion, food impaction, and heartburn were 
more prevalent in patients aged 7 to 17 years. 
The search results for specific serum IgE (ImmunoCAP®) 
are summarized in Table 2. Of the 43 patients studied, 18 
(41.9%) had sensitization to more than one food protein 
or aeroallergens, 2 (4.6%) were sensitive to one studied 
protein, and the remaining 23 (53.5%) patients presented 
no sensitization.
Regarding the endoscopic findings of the 43 patients 
on admission, whitish plaques on the esophagus mucosa 
predominated in 12 (27.9%), longitudinal grooves in 8 (18.6%) 
patients, whereas in 18 (41.2%) the macroscopic esophageal 
aspect was normal. At the microscopy, the quantification of 
eosinophils/HPF varied from 15-100 eosinophils per HPF, 
with the highest concentration of eosinophils in the lesions 
characterized as whitish plaques, as shown in Table 3. It 
was also observed that the proportion of patients with the 
number of eosinophils between 15 and 30 per field in normal 
endoscopies (44.4%, 8/18) was higher than in those with 
endoscopic findings suggestive of EoE with higher eosinophil 
count (8.0%, 2/23, p = 0.009, Fisher’s exact test).
The dietary and drug treatments were initially carried 
out for a period of three months. The dietary management 
was based on clinical history and the results of allergy 
tests, using the exclusion of identified allergen(s) in the 
clinical history and Rast ImmunoCAP®, or by eliminating 
the six major allergens (cow’s milk, soy, egg, fish, 
peanuts, and wheat) in patients where it was not possible 
to identify them through the clinical history and/or food 
allergy test.
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In four patients younger than 2 years, hypoallergenic 
formulas were used: protein hydrolyzate (2 cases) and 
amino acid formula (2 cases). In one child older than 2 
years of age, a free amino acid formula was used, due to 
nutritional problems. 
Of the 43 cases studied, 41 received topical glucocorticoids, 
and only two patients received oral corticosteroids, due to 
the young age. All 43 patients received acid suppression 
with PPIs as adjuvant treatment. 
33 (76.7%) of 43 patients received at least two courses 
of treatment, because when diet and medication were 
discontinued, the symptoms returned within four to eight 
weeks; however, after the second course of treatment, all 
patients were asymptomatic. 
Of the 43 patients, 28 agreed to undergo a control 
endoscopy. Table 4 shows that the six patients who had 
a normal endoscopy at baseline remained with a normal 
endoscopy, while of the 22 who initially had endoscopic 
Table 1 Symptom distribution in 43 patients according to age range.
Clinical manifestation  Age range   p
 < 7 years 7-17 years Total  
 n = 18 n = 25 n = 43
Nausea/vomiting 18 (100.0%) 5 (20.0%) 23 (53.5%) 0.000
Abdominal pain  18 (100.0%) 7 (28.0%) 25 (58.0%) 0.000a
Loss of appetite 10 (55.5%) 15 (60.0%) 25 (58.0%) 0.983a
Weight loss 1 (5.5%) 4 (16.0%) 5 (11.5%) 0.380b
Food aversion 0 (0%) 10 (40.0%) 10 (23.0%) 0.002b
Food impaction 0 (0%) 12 (48.0%) 12 (28.0%) 0.005b
Heartburn 0 (0%) 13 (52.0%) 13 (30.0%) 0.000a
Wheezing 7 (38.8%) 12 (48.0%) 19 (44.0%) 0.777a,b
Coughing 5 (27.7%) 6 (24.0%) 11 (25.5%) 1.000b
aChi-squared test with Yates’ correction.
bFisher’s exact test.
Table 2 Number of patients with eosinophilic esophagitis with positive IgE antibody (RAST) to aeroallergens and food 
allergens according to age range. 
Specific IgE  Age range   p
 < 7 years 7-17 years Total 
 n = 18 n = 25 n = 43
Cow’s milk  8 (44.0%) 7 (28.0%) 15 (34.9%) 0.428a,b
Egg white 1 (5.5%) 2 (8.0%) 3 (7.0%) 1.000b
Fish  1 (5.5%) 1 (4.0%) 2 (4.5%) 1.000b
Peanuts  2 (11.0%) 1 (4.0%) 3 (7.0%) 0.562b
Soybean 2 (11.0%) 2 (8.0%) 4 (9.0%) 1.000b
Wheat 0 (0%) 0 (0%) 0 (0%) Non-analyzable
House dust 4 (22.0%) 12 (48.0%) 16 (37%) 0.159a
aChi-squared test with Yates’ correction.
bFisher’s exact test.
Table 3 Association between endoscopic lesion severity and intensity of eosinophilic infiltrate in 43 patients with 
eosinophilic esophagitis.
 Eosinophil counts per high-power field
 Total 15-30 31-50 > 50
Concentric rings 2 1 1 0
Longitudinal grooves 8 0 4 4
Whitish plaques 12 0 0 12
Longitudinal grooves + whitish plaques 3 1 2 0
Normal  18 8 8 2
Total 43 10 15 18
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abnormalities, eight had normal esophageal mucosa in the 
second endoscopy (McNemar’s test, p = 0.013). Regarding 
eosinophil count, initially all patients had increased 
eosinophil count (10 patients with 15 to 30 eosinophils; 10 
with 31-50 eosinophils; and 8 with eosinophil count > 50). 
All had fewer than 15 eosinophils in the second biopsy after 
treatment. 
Discussion
The Brazilian scientific literature on EoE in the pediatric 
population is limited to two case series described by 
Cury et al.3 and by Ferreira et al.,4 highlighting symptom 
refractoriness to standard treatment of GERD in both 
articles. Another report8 emphasized EoE as differential 
diagnosis of achalasia. In the present study, the clinical 
and endoscopic manifestations and response to therapy of 
43 patients treated in the period between February 2004 
and September 2010 and whose final diagnosis was the 
classic form of EoE are described. The subgroup of patients 
with EoE responsive to PPIs, in relation to symptoms and 
histopathological findings were not included, as all patients 
were combined before the inclusion of this subgroup in the 
updated EoE criteria.5
Additionally, the updated consensus included a small 
number of patients with fewer than 15 eosinophils/HPF, 
who are treated with PPIs, provided they show other 
signs of eosinophilic inflammation, including eosinophilic 
microabscesses, accumulation of eosinophils in the 
superficial layer of the esophageal mucosa, or extracellular 
eosinophilic granules. The reasons pointed out by 
researchers were the possibility of inadequate biopsies, 
sample errors, and coping with chronic disease or partial 
response to treatment. The present study did not evaluate 
these histological findings, considering only the infiltration 
of at least 15 eosinophils/HPF.5
The mean age of the patients at diagnosis was 8.4 years 
(1 month to 17 years); patients were predominantly males 
(86%), and the majority were white. Although it appears to 
be an absolute majority, racial classification by skin color 
is controversial, especially in Brazil, where miscegenation 
is high. The mean age of disease prevalence was similar 
to that in the literature.9 There is also agreement in the 
literature on male predominance.10-15
It is interesting to stress that this disease has been 
described in all continents, except for Africa, probably due 
to the absence of the gene(s) responsible for the disease or 
absence of environmental factors.16
Another aspect to highlight is that these patients 
were treated during a six-year period, and most patients 
were referred from the Pediatric Gastroenterology 
outpatient clinic of the Complexo Hospitalar do Mandaqui, 
corresponding to the frequency of 7 patients/year; 
however, there are no data on the total of patients 
presenting with suspected GERD/year and responders to 
PPIs during this period, among which the subset of EoE 
responders to PPIs, who did not participate in this study, 
was found. 
Some authors have called attention to the increasing 
prevalence of EoE in children and adolescents.11,12,17 
When comparing the prevalence of symptoms in the 
present study with those of other authors, an agreement 
in the variability in clinical presentation according to age 
was observed; most symptoms of nausea, vomiting, and 
abdominal pain were observed in children younger than 7 
years, while heartburn, food aversion, and food impaction 
were mostly observed in children older than 7 years and 
adolescents.7,9,10,13,14
Regarding the presence of atopy, respiratory symptoms 
were observed, such as recurrent wheezing (44%) and 
cough (25.5%), which reinforced the suspicion of EoE; these 
findings are similar to those found by other authors.12,14 
Endoscopic findings suggestive of EoE at the diagnosis 
were observed in 58% of case, and apparently normal 
esophageal mucosa were found in 42% of cases. Other 
studies showed endoscopic alterations suggestive of EoE 
in greater proportions, around 73% of cases.7,10,14 Although 
none of these endoscopic findings is pathognomonic of EoE, 
finding at least one of them is strongly suggestive of the 
disease. It is noteworthy that some of the present patients 
had an initial diagnosis of monilial esophagitis, due to the 
endoscopic finding of whitish plaques on the esophageal 
mucosa. 
Table 4 Evolution analysis of endoscopic findings in 28 patients with eosinophilic esophagitis who underwent control 
evaluation nine to 12 months after treatment initiation.
 Before treatment 
After treatment Concentric  Longitudinal Whitish Longitudinal Normal Total 
 rings grooves plaques grooves + whitish  
    plaques 
Concentric rings 2     2
Longitudinal grooves  6    6
Whitish plaques   5   5
Longitudinal grooves +     1  1 
whitish plaques
Normal  2 5 1 6 14
Total 2 8 10 2 6 28
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Regarding the histological aspects, at least two 
fragments were obtained from the esophageal mucosa 
for the quantification of eosinophils/HPF. The literature 
recommends obtaining at least one fragment in each 
esophageal segment (proximal-medium and distal) as 
esophageal inflammation may be focal and involve 
apparently healthy areas.5,7 This procedure increases the 
diagnostic sensitivity to 97% of cases.18
Eosinophilic infiltration of 15-30 per HPF was found in 
89% of apparently normal mucosa, probably because the 
eosinophilic inflammatory infiltrate had not yet reached the 
mucosa and thus had not manifested any lesions suggestive 
of the disease.
The determination of specific IgE only assists in 
identifying IgE-mediated food allergy of type I or immediate 
type.6 The detection of specific IgE has been considered 
indicative of sensitization to food, confirmed only after its 
exclusion, with improvement of all symptoms and return 
of symptoms after oral provocation test.19 Regarding the 
research of aeroallergens through tests involving specific 
IgE, there have been only case reports in adults showing its 
probable role in the triggering of EoE.20 Among the patients 
evaluated in this study, the presence of sensitization by 
cow’s milk protein was found in 15 (34.9%) patients, and 
by aeroallergens in 16 (37.0%) patients identified through 
ImmunoCAP. The frequency of sensitization (positive 
ImmunoCAP) to inhalants and foods in this group of patients 
was 46.5%, which should be compared with previously 
published Brazilian data in normal and atopic children of 
25.8% and 79%, respectively.21
The treatment of these patients involved dietary therapy, 
with the exclusion of the main allergenic foods (cow’s milk, 
soy milk, eggs, fish, peanuts, and wheat) when allergens 
were not identified through clinical history or ImmunoCAP 
performed as indicated in literature.5,7,22
The use of the elemental formula diet removes all 
potential food allergens, and is especially indicated for 
infants, whose oral intake tolerance is increased.23
After histological confirmation of EoE, in addition to 
dietary therapy, patients received topical steroids with 
spray inhalers (41/43) or by oral route for children younger 
than 2 years (2/43). Studies have shown that the use of 
systemic or topical corticosteroids has been effective in 
resolving the clinical and pathological manifestations of 
EoE, but its systemic use must be reserved for severe 
cases.14,24,25
The use of topical corticosteroids for the maintenance 
treatment of EoE in adults and children has not been 
established, as well as dose, frequency, and mode of 
administration, as these formulations were not designed 
for use in the esophagus.5,7,24 The doses suggested by 
the current literature vary from 440 to 880 mcg/day for 
children and 880-1760 mcg/day for adolescents and adults, 
continuously for six to eight weeks. 
28 of 43 patients underwent control endoscopy; clinical, 
endoscopic, and histological improvement was observed 
between six and nine months after treatment, with a 
decrease in the number of eosinophils/HPF to approximately 
0-12 eosinophils/HPF.
It is noteworthy the fact that 75% of patients remained 
temporarily asymptomatic after finishing the first 
treatment cycle and withdrawing medication; however, 
after exposure to food allergens, they started to present 
the same symptoms again, requiring a second treatment 
cycle. The clinical outcome of the present patients with 
EoE, although chronic, was satisfactory. There was no loss 
of patients during outpatient follow-up; however, parents 
or guardians of the patients did not always accept the 
performance of a third upper endoscopic assessment.
Treatment duration has not been established, nor has the 
importance of treating asymptomatic patients who remain 
with histological signs of EoE after initial treatment and the 
frequency of endoscopic controls during follow-up.5
Patients gained quality of life, reflected by changes in 
feeding behavior reported by the parents, demonstrating 
improved mood and better social behavior, and began to 
have meals with their families once again. The families 
felt gratified and many felt embarrassed of having wrongly 
classified their children as being too selective and as having 
a social disorder. 
In patients with the classic form of EoE, symptoms vary 
according to age, with nausea, vomiting, and abdominal 
pain most often found in young children, and lack of 
appetite, heartburn, and food impaction in older children 
and adolescents. Patients with suspected EoE should 
undergo biopsies in the proximal and distal locations of 
the esophagus, stomach, and duodenum, in order to attain 
a complete diagnosis. A favorable response to treatment 
from the clinical and histological standpoint was achieved 
by all patients, requiring at least two treatment cycles in 
76.7% of 43 patients.
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